As specialty drug costs, formulary wars, and reimbursement models grab headlines everyday, we need to take a step back and visualize how all of this might impact innovation and whether the patient stands to lose in the process.
Powerful clinical decision support tools harnessing the potential of big data analytics may make it easier for physicians to set their patients on a standardized road to improvement, but the expansion of pre-approved, packed care may be doing more than just lowering costs. In places where bundled payments based on holistic episodes of care has taken root, these evidence-based, standardized clinical pathways may be having a negative impact on innovation and experimentation that can help those patients that fall outside of treatment methods that receive a payer stamp of approval.
While precision medicine, genomics, and personalized care are becoming big talking points in the research community, is the trend towards financial rewards for a relatively narrow band of evidence-based medicine limiting discovery by making less common treatments too expensive to use routinely?
Link to the complete article on HealthIT Analytics:
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More